Stockwatch: Investors Reward Rose-Tinted Guidance
But It Will Come Out In The Second-Quarter Wash
Executive Summary
After three weeks of the first-quarter 2020 earnings season, the coronavirus pandemic has left pure-play pharmaceutical companies in a much better position than many other sectors. One of the reasons behind this has been channel stocking. As some companies have learnt in the past, this can be a double-edged sword.